References
Maier W, Zobel A, Wagner M (2006) Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry 19(2):165–170
Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62(11):1310–1316
Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263(5):367–377
Hashimoto K (2014) Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 18(9):1049–1063
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60(6):572–576
Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, Okuno A, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol Psychiatry 57(12):1493–1503
Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. Plos One 9(7):e101652
Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M (2005) Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29(5):767–769
Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G (2007) A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 90(1–3):41–51
The Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427
Habl G, Zink M, Petroianu G, Bauer M, Schneider-Axmann T, von Wilmsdorff M, Falkai P, Henn FA, Schmitt A (2009) Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. J Neural Transm 116(12):1657–1665
Pålsson E, Jakobsson J, Södersten K, Fujita Y, Sellgren C, Ekman CJ, Ågren H, Hashimoto K, Landén M (2015) Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur Neuropsychopharmacol 25(1):133–140
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214
Lahti AC, Weiler MA, Tamara M, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25(4):455–467
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793–802
Moaddel R, Luckenbaugh DA, Xie Y, Villaseñor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Garcia A, Bernier M, Torjman MC, Barbas C, Zarate CA Jr, Wainer IW (2015) d-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology 232(2):399–409
Hashimoto K (2014) Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology 231(20):4081–4082
Acknowledgments
This study was supported by a grant from Comprehensive Research on Disability, Health and Welfare, Health and Labour Sciences Research Grants, Japan.
Conflict of interest
Dr. Hashimoto is a holder of the patents “Method of examining and diagnosing schizophrenia” (US 2005/0164400 A1), which pertain to the measurement of d-serine as a biomarker. In addition, Dr. Hashimoto has served as a scientific consultant to Astellas, Dainippon-Sumitomo, and Taisho, and he has also received research support from Abbvie, Dainippon-Sumitomo, Mochida, Otsuka, and Taisho.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hashimoto, K. Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 266, 83–85 (2016). https://doi.org/10.1007/s00406-015-0602-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-015-0602-4